Reported Saturday, Aptose Tuspetinib TUS+VEN+AZA Triplet Shows High Rates Of Efficacy And MRD-Negative Remissions In Newly Diagnosed AML Patients

Benzinga·12/08/2025 09:33:40

語音播報

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations
Safety continues to be a notable hallmark of TUS-based therapies
100% response rate (CR/CRh) at the two higher dose levels (80 and 120 mg TUS dose)
CR/CRh observed in FLT3 wildtype subjects, representing ~70% of AML patients
CR/CRh observed in AML with TP53/complex karyotype, RAS, and MDS-related mutations